Do analysts rate QSI or CSBR?

Quantum-Si presently has a consensus target price of $2.50, suggesting a potential upside of 90.84%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts plainly believe Quantum-Si is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum-Si 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to QSI or CSBR?

In the previous week, Quantum-Si had 3 more articles in the media than Champions Oncology. MarketBeat recorded 5 mentions for Quantum-Si and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.31 beat Quantum-Si's score of 0.34 indicating that Champions Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum-Si 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Champions Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NAUT or CSBR?

Nautilus Biotechnology presently has a consensus price target of $3.83, suggesting a potential upside of 77.47%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nautilus Biotechnology 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to NAUT or CSBR?

In the previous week, Nautilus Biotechnology had 1 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Nautilus Biotechnology and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.31 beat Nautilus Biotechnology's score of 1.27 indicating that Champions Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nautilus Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Champions Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer QTRX or CSBR?

Quanterix presently has a consensus price target of $3.25, indicating a potential upside of 5.86%. Given Quanterix's stronger consensus rating and higher probable upside, equities research analysts plainly believe Quanterix is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quanterix 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CDXS or CSBR?

Codexis currently has a consensus price target of $6.50, suggesting a potential upside of 377.94%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SEER or CSBR?

Seer presently has a consensus target price of $4.00, indicating a potential upside of 96.08%. Given Seer's stronger consensus rating and higher possible upside, research analysts clearly believe Seer is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seer 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SEER or CSBR more profitable?

Champions Oncology has a net margin of -1.82% compared to Seer's net margin of -478.05%. Champions Oncology's return on equity of -25.77% beat Seer's return on equity. Company Net Margins Return on Equity Return on Assets Seer -478.05% -27.23% -23.99% Champions Oncology -1.82% -25.77% -3.71%

Champions Oncology (CSBR) Competitors

$4.79 -0.02 (-0.42%)

Closing price 10/15/2026 03:59 PM Eastern

Extended Trading

$4.80 +0.01 (+0.21%)

As of 10/15/2026 05:01 PM Eastern

Compare

CSBR vs. QSI, NAUT, QTRX, CDXS, and SEER

Should you buy Champions Oncology stock or one of its competitors? Champions Oncology's main competitors and comparable companies include Quantum-Si (QSI), Nautilus Biotechnology (NAUT), Quanterix (QTRX), Codexis (CDXS), and Seer (SEER). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Champions Oncology compare to Quantum-Si?

Quantum-Si (NASDAQ:QSI) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Champions Oncology has higher revenue and earnings than Quantum-Si. Champions Oncology is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum-Si	$2.44M	117.51	-$101.34M	-$0.46	N/A
Champions Oncology	$59.42M	1.12	-$1.17M	-$0.08	N/A

Quantum-Si has a beta of 3.21, suggesting that its share price is 221% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

39.9% of Quantum-Si shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 22.0% of Quantum-Si shares are owned by insiders. Comparatively, 46.3% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Quantum-Si had 3 more articles in the media than Champions Oncology. MarketBeat recorded 5 mentions for Quantum-Si and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.31 beat Quantum-Si's score of 0.34 indicating that Champions Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum-Si	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Champions Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quantum-Si presently has a consensus target price of $2.50, suggesting a potential upside of 90.84%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts plainly believe Quantum-Si is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Champions Oncology has a net margin of -1.82% compared to Quantum-Si's net margin of -6,138.26%. Champions Oncology's return on equity of -25.77% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum-Si	-6,138.26%	-47.12%	-43.18%
Champions Oncology	-1.82%	-25.77%	-3.71%

Summary

Champions Oncology beats Quantum-Si on 9 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Nautilus Biotechnology has a net margin of 0.00% compared to Champions Oncology's net margin of -1.82%. Champions Oncology's return on equity of -25.77% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Champions Oncology	-1.82%	-25.77%	-3.71%

Nautilus Biotechnology presently has a consensus price target of $3.83, suggesting a potential upside of 77.47%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 46.3% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Nautilus Biotechnology had 1 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Nautilus Biotechnology and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.31 beat Nautilus Biotechnology's score of 1.27 indicating that Champions Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Champions Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Champions Oncology has higher revenue and earnings than Nautilus Biotechnology. Champions Oncology is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Champions Oncology	$59.42M	1.12	-$1.17M	-$0.08	N/A

Nautilus Biotechnology has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Summary

Nautilus Biotechnology beats Champions Oncology on 8 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to Quanterix?

Quanterix (NASDAQ:QTRX) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Champions Oncology has lower revenue, but higher earnings than Quanterix. Champions Oncology is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	1.05	-$107.15M	-$2.63	N/A
Champions Oncology	$59.42M	1.12	-$1.17M	-$0.08	N/A

Quanterix has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Champions Oncology has a net margin of -1.82% compared to Quanterix's net margin of -80.25%. Champions Oncology's return on equity of -25.77% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
Champions Oncology	-1.82%	-25.77%	-3.71%

Quanterix presently has a consensus price target of $3.25, indicating a potential upside of 5.86%. Given Quanterix's stronger consensus rating and higher probable upside, equities research analysts plainly believe Quanterix is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Champions Oncology had 1 more articles in the media than Quanterix. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Quanterix. Quanterix's average media sentiment score of 1.56 beat Champions Oncology's score of 1.31 indicating that Quanterix is being referred to more favorably in the media.

Company	Overall Sentiment
Quanterix	Very Positive
Champions Oncology	Positive

86.5% of Quanterix shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 1.5% of Quanterix shares are owned by company insiders. Comparatively, 46.3% of Champions Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Champions Oncology beats Quanterix on 8 of the 14 factors compared between the two stocks.

How does Champions Oncology compare to Codexis?

Codexis (NASDAQ:CDXS) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Champions Oncology has lower revenue, but higher earnings than Codexis. Champions Oncology is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.12	-$43.97M	-$0.34	N/A
Champions Oncology	$59.42M	1.12	-$1.17M	-$0.08	N/A

In the previous week, Codexis had 1 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Codexis and 2 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.31 beat Codexis' score of -0.06 indicating that Champions Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Codexis	Neutral
Champions Oncology	Positive

Codexis has a beta of 2.55, meaning that its share price is 155% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Codexis currently has a consensus price target of $6.50, suggesting a potential upside of 377.94%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

78.5% of Codexis shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 3.5% of Codexis shares are held by company insiders. Comparatively, 46.3% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Champions Oncology has a net margin of -1.82% compared to Codexis' net margin of -39.55%. Champions Oncology's return on equity of -25.77% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Champions Oncology	-1.82%	-25.77%	-3.71%

Summary

Codexis beats Champions Oncology on 8 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to Seer?

Seer (NASDAQ:SEER) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Seer has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Seer presently has a consensus target price of $4.00, indicating a potential upside of 96.08%. Given Seer's stronger consensus rating and higher possible upside, research analysts clearly believe Seer is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Champions Oncology has higher revenue and earnings than Seer. Champions Oncology is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58M	6.81	-$73.60M	-$1.22	N/A
Champions Oncology	$59.42M	1.12	-$1.17M	-$0.08	N/A

Champions Oncology has a net margin of -1.82% compared to Seer's net margin of -478.05%. Champions Oncology's return on equity of -25.77% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-478.05%	-27.23%	-23.99%
Champions Oncology	-1.82%	-25.77%	-3.71%

75.2% of Seer shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 11.3% of Seer shares are held by company insiders. Comparatively, 46.3% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Champions Oncology had 1 more articles in the media than Seer. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Seer. Champions Oncology's average media sentiment score of 1.31 beat Seer's score of 0.59 indicating that Champions Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Seer	Positive
Champions Oncology	Positive

Summary

Champions Oncology beats Seer on 9 of the 15 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSBR vs. The Competition

Export

Metric	Champions Oncology	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$66.95M	$10.67B	$7.31B	$12.93B
Dividend Yield	N/A	1.45%	2.51%	19.61%
P/E Ratio	N/A	22.91	212.19	20.44
Price / Sales	1.12	103.75	582.56	86.48
Price / Cash	330.67	27.22	76.19	51.56
Price / Book	16.52	6.21	10.42	6.01
Net Income	-$1.17M	$56.67B	$3.50B	$380.68M
7 Day Performance	-2.96%	-1.58%	-3.29%	-3.16%
1 Month Performance	-3.23%	5.08%	-6.56%	-5.20%
1 Year Performance	-26.31%	21.77%	2.69%	-4.08%

Champions Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSBR Champions Oncology	0.2895 of 5 stars	$4.79 -0.4%	N/A	-28.0%	$66.95M	$59.42M	N/A	214	Positive News
QSI Quantum-Si	3.5965 of 5 stars	$1.28 +4.9%	$2.50 +95.3%	-50.2%	$267.04M	$2.44M	N/A	145	News Coverage Gap Down
NAUT Nautilus Biotechnology	3.1427 of 5 stars	$1.96 +10.7%	$3.83 +95.6%	+96.4%	$225.24M	N/A	N/A	130	News Coverage Positive News Gap Down High Trading Volume
QTRX Quanterix	1.2748 of 5 stars	$3.33 -3.2%	$3.00 -9.9%	-46.9%	$162.69M	$138.90M	N/A	450	Positive News Analyst Forecast
CDXS Codexis	2.3982 of 5 stars	$1.41 +3.7%	$6.50 +361.0%	-50.4%	$148.93M	$70.39M	N/A	146	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSBR) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Champions Oncology (CSBR) Competitors

CSBR vs. QSI, NAUT, QTRX, CDXS, and SEER

How does Champions Oncology compare to Quantum-Si?

Summary

How does Champions Oncology compare to Nautilus Biotechnology?

Summary

How does Champions Oncology compare to Quanterix?

Summary

How does Champions Oncology compare to Codexis?

Summary

How does Champions Oncology compare to Seer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Champions Oncology (CSBR) Competitors

CSBR vs. QSI, NAUT, QTRX, CDXS, and SEER

How does Champions Oncology compare to Quantum-Si?

Which has preferable valuation & earnings, QSI or CSBR?

Which has more risk and volatility, QSI or CSBR?

Do institutionals & insiders believe in QSI or CSBR?

Does the media refer more to QSI or CSBR?

Do analysts rate QSI or CSBR?

Is QSI or CSBR more profitable?

Summary

How does Champions Oncology compare to Nautilus Biotechnology?

Is NAUT or CSBR more profitable?

Do analysts prefer NAUT or CSBR?

Do insiders & institutionals hold more shares of NAUT or CSBR?

Does the media refer more to NAUT or CSBR?

Which has better earnings and valuation, NAUT or CSBR?

Which has more risk & volatility, NAUT or CSBR?

Summary

How does Champions Oncology compare to Quanterix?

Which has stronger valuation and earnings, QTRX or CSBR?

Which has more volatility & risk, QTRX or CSBR?

Is QTRX or CSBR more profitable?

Do analysts prefer QTRX or CSBR?

Does the media favor QTRX or CSBR?

Do insiders and institutionals believe in QTRX or CSBR?

Summary

How does Champions Oncology compare to Codexis?

Which has better valuation and earnings, CDXS or CSBR?

Does the media favor CDXS or CSBR?

Which has more volatility and risk, CDXS or CSBR?

Do analysts rate CDXS or CSBR?

Do insiders & institutionals hold more shares of CDXS or CSBR?

Is CDXS or CSBR more profitable?

Summary

How does Champions Oncology compare to Seer?

Which has more risk and volatility, SEER or CSBR?

Do analysts recommend SEER or CSBR?

Which has better valuation and earnings, SEER or CSBR?

Is SEER or CSBR more profitable?

Do institutionals and insiders believe in SEER or CSBR?

Does the media favor SEER or CSBR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools